Healthpeak Properties (DOC) has reiterated its commitment to disciplined capital allocation, maintaining a covered quarterly dividend and preserving balance sheet flexibility. Management plans to prioritize high-return opportunities over market timing, targeting assets with unlevered internal rates of return (IRRs) in the low double digits. This approach underscores the REIT’s long-term income strategy and supports a sustainable payout ratio below 80% of funds from operations (FFO).

DOC intends to recycle more than $1 billion from outpatient medical properties into its lab portfolio, where demand from biotech tenants remains robust despite sector headwinds. The company is targeting unlevered IRRs in the mid-teens on these lab investments, driven by strong pre-leasing commitments and a technology-enabled build-to-suit model. Management believes this redeployment will enhance portfolio returns and deepen its position in high-barrier science markets such as Boston, San Francisco and San Diego.

Both the lab and outpatient medical segments show improving leasing pipelines, with over 40% of lab space under active negotiation and outpatient medical renewals trending above 75%. DOC projects quarterly portfolio occupancy will bottom in the high-70s percentage range before recovering over the next 12 to 18 months. Lease extensions and tenant expansion options in key markets are expected to mitigate near-term vacancy pressure.

The CCRC segment delivered another quarter of strong net operating income growth, with same-store NOI up approximately 5.5% year over year. Demand for senior housing units remains steady, and DOC has locked in average annual rent escalations of 2.5% across its CCRC portfolio. Management plans targeted capital improvements in select communities to drive ancillary revenue streams such as wellness programming and hospitality services.